AVITA - Regenerative Dermatology
Epidermolysis Bullosa (EB) is a group of rare and incurable skin disorders caused by mutations in genes encoding structural proteins resulting in skin fragility and blistering, leading to chronic wounds and, in some sub-types, an increased risk of squamous cell carcinoma or death. Dystrophic EB is estimated to affect 3-8 million people[1], and there is currently no FDA-approved treatment.
Currently, AVITA Medical and scientists at the Gates Center for Regenerative Medicine at the University of Colorado School of Medicine are collaborating on preclinical research to establish proof of concept and explore further development of a spray-on treatment of genetically modified cells for patients with EB, with potential applicability to other genetic skin disorders. The partnership pairs AVITA Medical’s patented and proprietary Spray-On Skin™ Cells technology and expertise with the Gates Center’s innovative, patent-pending combined reprogramming and gene-editing technology to allow cells to function properly.
More than 3 million aesthetic procedures are performed in the U.S. annually aimed to improve skin tightness, texture, and evenness in skin tone.